3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Prostatic Neoplasms
23
Breast Neoplasms
16
Neoplasms by Site
2
Neoplasms
2
Neoplasm Metastasis
2
Breast Diseases
2
Stage II Prostate Adenocarcinoma
1
Skin Diseases
1
Sexual Dysfunctions, Psychological
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms, Castration-Resistant
1
Prostate Cancer Metastatic Disease
1
Prostate Cancer Metastatic
1
Ovarian Neoplasms
1
Oligometastatic Prostate Carcinoma
1
Metastatic Neuroendocrine Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer
1
Metastatic Castration-Resistant Prostate Cancer
1
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
1
Endometrial Neoplasms
1
Dementia
1
Cognitive Dysfunction
1
Anatomic Stage III Breast Cancer AJCC v8
1
Advanced Breast Cancer
1
Interventions
pembrolizumab
90
Blood Specimen Collection
41
Cyclophosphamide
37
Bevacizumab
36
Nivolumab
35
Standard of Care
32
Carboplatin
31
Surveys and Questionnaires
29
Paclitaxel
27
atezolizumab
25
Exercise
25
Pemetrexed
24
Gemcitabine
23
Cisplatin
23
Fluorouracil
22
Radiotherapy
20
Leucovorin
20
Dexamethasone
20
Docetaxel
19
Oxaliplatin
18
Rituximab
16
Irinotecan
16
Cetuximab
16
dostarlimab
15
Drug Therapy
15
Doxorubicin
15
Ipilimumab
14
Biopsy
14
130-nm albumin-bound paclitaxel
14
fludarabine
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms
×
Gonadotropin-Releasing Hormone
×
1 year
×
Clear all
NCT04964934
2026-04-21
SERENA-6
AstraZeneca
Phase 3
Active not recruiting
315 enrolled
NCT04711252
2025-10-14
SERENA-4
AstraZeneca
Phase 3
Active not recruiting
1,370 enrolled